Brief: Urogen Pharma reports wider-than-expected fourth-quarter loss
10/03/2025 14:56
March 10 (Reuters) - Urogen Pharma Ltd UR8.F: UROGEN PHARMA Q4 OPERATING EXPENSES USD 49.752 MILLION UROGEN PHARMA Q4 BASIC EPS USD -0.8 UROGEN PHARMA Q4 OPERATING INCOME USD -27.658 MILLION VERSUS. IBES ESTIMATE USD -22.3 MILLION UROGEN PHARMA Q4 PRETAX PROFIT USD -34.863 MILLION VERSUS. IBES ESTIMATE USD -28.6 MILLION UROGEN PHARMA Q4 REVENUE USD 24.565 MILLION VERSUS. IBES ESTIMATE USD 25.6 MILLION UROGEN PHARMA Q4 NET INCOME USD -37.512 MILLION VERSUS. IBES ESTIMATE USD -28.5 MILLION Source text: nBw6s452fa Further company coverage: UR8.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors